Resistance to voriconazole due to a G448S substitution in Aspergillus fumigatus in a patient with cerebral aspergillosis

Journal of Clinical Microbiology

Volumn 50, Issue 7, 2012, Pages 2531-2534

  Pelaez, Teresa ^a,b   Gijón, Paloma ^a   Bunsow, Eleonora ^a   Bouza, Emilio ^a,b   Sánchez Yebra, Waldo ^c   Valerio, Maricela ^a   Gama, Beatriz ^a   Cuenca Estrella, Manuel ^d   Melladod, Emilia ^d  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL TORRECÁRDENAS   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ADULT; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; BRAIN ABSCESS; BRAIN BIOPSY; BRAIN SURGERY; CASE REPORT; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; CEREBROSPINAL FLUID DRAINAGE; CHOLESTEATOMA; CHRONIC OTITIS MEDIA; COCHLEOSTOMY; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR SURGERY; FACIAL NERVE PARALYSIS; FEMALE; FUNGAL EXAMINATION; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HUMAN; HUMAN TISSUE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; OTORRHEA; PETROSECTOMY; PONS ANGLE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; TREATMENT DURATION;

AMINO ACID SUBSTITUTION; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; FEMALE; FUNGAL PROTEINS; HUMANS; MIDDLE AGED; MUTATION, MISSENSE; NEUROASPERGILLOSIS; PYRIMIDINES; SPAIN; TRIAZOLES;

EID: 84862726659     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00329-12     Document Type: Article

References (33)

1. Alcazar-Fuoli L, et al. 2008. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob. Agents Chemother. 52:1244-1251.
2. Arendrup MC, et al. 2010. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One 5:e10080.
3. Bellete B, et al. 2010. Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma. Med. Mycol. 48:197-200.
4. Bueid A, et al. 2010. Azole antifungal resistance in Aspergillus fumigatus 2008 and 2009. J. Antimicrob. Chemother. 65:2116-2118.
5. Chen J, Li H, Li R, Bu D, Wan Z. 2005. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J. Antimicrob. Chemother. 55:31-37.
6. Chryssanthou E. 1997. In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. Acquired resistance to itraconazole. Scand. J. Infect. Dis. 29:509-512.
7. Dannaoui E, et al. 2001. Acquired itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. 47:333-340.
8. Denning DW, et al. 1997. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 41:1364-1368.
9. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. 2003. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:1120-1124.
10. Espinel-Ingroff A, et al. 2010. Wild-Type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48:3251-3257.
11. Espinel-Ingroff A, Rezusta A. 2002. E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method. J. Clin. Microbiol. 40:2101-2107.
12. Herbrecht R, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408 415.
13. Howard SJ, et al. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
14. Howard SJ, et al. 2006. Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents 28:450-453.
15. Kelly SL, Lamb DC, Loeffler J, Einsele H, Kelly DE. 1999. The G464S amino acid substitution in Candida albicans sterol 14alpha-demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochem. Biophys. Res. Commun. 262:174-179.
16. Lionakis MS, et al. 2005. Increased frequency of non-fumigatus Aspergillus species in amphotericin B or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn. Microbiol. Infect. Dis. 52:15-20.
17. Manavathu E, Espinel-Ingroff A, Alangaden G, Chandrasekar P. 2003. Molecular studies on voriconazole resistance in a clinical isolate of Aspergillus fumigatus, abstr M-392. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., Chicago IL. American Society for Microbiology, Washington, DC.
18. Manavathu E, Baskaran I, Krishnan S, Alangaden G, Chandrasekar P. 2003. Molecular cytochrome P450 14-alpha-sterol demethylase mutation-dependent triazole cross-resistance in Aspergillus fumigatus, abstr M-471. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., Chicago IL. American Society for Microbiology, Washington, DC.
19. Mann PA, et al. 2003. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob. Agents Chemother. 47:577-581.
20. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. 2004. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob. Agents Chemother. 48:2747-2750.
21. Mellado E, et al. 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51:1897-1904.
22. Mortensen KL, et al. 2010. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob. Agents Chemother. 54:4545-4549.
23. Pappas PG, et al. 2010. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 50:1101-1111.
24. Pfaller MA, et al. 2008. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J. Clin. Microbiol. 46:2568-2572.
25. Rodero L, et al. 2003. G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob. Agents Chemother. 47:3653-3656.
26. Rodriguez-Tudela JL, et al. 2008. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52:2468-2472.
27. Sanglard D, Ischer F, Koymans L, Bille J. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42:241-253.
28. Snelders E, et al. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5:e219.
29. Stevens DA, Melikian GL. 2011. Aspergillosis in the 'nonimmunocompromised'host. Immunol. Invest. 40:751-766.
30. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). 2008. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14: 982-984.
31. van der Linden JW, et al. 2011. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg. Infect. Dis. 17:1846-1854.
32. Verweij PE, Mellado E, Melchers WJ. 2007. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356:1481-1483.
33. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. 2009. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect. Dis. 9:789-795.